BPI binds LPS on the bacterial surface

Stable Identifier
Reaction [binding]
Homo sapiens
Locations in the PathwayBrowser
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

Bactericidal permeability-increasing protein (BPI) is a 57-kDa cationic antimicrobial protein that is present principally in the azurophilic granules of polymorphonuclear leukocytes (Elsbach P 1998). BPI has both heparin- and LPS-binding capacity and displays anti-inflammatory activity and direct bactericidal action toward Gram-negative bacteria (Ooi CE et al. 1991; Weiss J et al. 1992; Levy O et al. 2000). Direct bactericidal activity and lipopolysaccharide neutralization are mediated by the N-terminal part of the protein, whereas the C-terminal region has been shown to opsonize bacteria (Iovine NM et al. 1997; Elsbach P & Weiss J 1998).

Antineutrophil cytoplasmic autoantibodies against BPI (BPI-ANCA) have been found in diseases of different etiologies, such as cystic fibrosis, TAP deficiency or inflammatory bowel diseases (Walmsley RS et al. 1997; Schultz H et al. 2004; Schinke S et al. 2004; Aichele D et al. 2006). The presence of BPI-ANCA has been shown to correlate with the chronic or profuse exposure of the host to Gram-negative bacteria and their endotoxin (Aebi C et al. 2000; Carlsson M et al. 2003; Schultz H et al. 2003; Schultz H 2007).

Entity On Other Cell
Orthologous Events
Cite Us!